<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246453</url>
  </required_header>
  <id_info>
    <org_study_id>EC07/90479</org_study_id>
    <nct_id>NCT01246453</nct_id>
  </id_info>
  <brief_title>Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema</brief_title>
  <official_title>A Prospective, Randomized, Double Blind, Controlled Trial to Evaluate Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Pleural Empyema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Objectives:

             -  Main objective: To evaluate the efficacy and safety of intrapleural alteplase vs
                urokinase in patients with complex complicated parapneumonic pleural effusion and
                empyema.

             -  To evaluate the pleural and plasmatic levels of the fibrinolytic system markers
                after the treatment with alteplase vs urokinase

             -  To evaluate the safety of alteplase in the treatment of complex complicated
                parapneumonic pleural effusion and empyema

        2. Design: Multicentric, randomized, parallel, controlled and double blind

        3. Main variable: Percentage of curation

        4. Study population and number of patients: 204 patients with complex complicated
           parapneumonic pleural effusions and empyema

        5. Duration of the treatment: Three days (main variable), and optional three days
           (secondary variable)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy and safety of intrapleural alteplase vs urokinase in patients with complex complicated parapneumonic pleural effusion and empyema during one year of follow-up.</measure>
    <time_frame>Evaluation at three and 6 days of treatment</time_frame>
    <description>It will be also an evaluation at one month, six months and one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pleural and plasmatic levels of the fibrinolytic system markers after the treatment with alteplase vs urokinase</measure>
    <time_frame>Evaluation at three and 6 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Empyema, Pleural</condition>
  <condition>Pleural Effusion</condition>
  <condition>Pleural Diseases</condition>
  <arm_group>
    <arm_group_label>urokinase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrapleurally Alteplase vs Intrapleurally Urokinase</intervention_name>
    <description>Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days</description>
    <arm_group_label>urokinase</arm_group_label>
    <arm_group_label>Alteplase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Empyema and Complex Complicated Parapneumonic Pleural Effusion

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Critically illness

          -  Systemic anticoagulant treatment

          -  Coagulation Disorder

          -  Bronchopleural fistula

          -  Active bleeding

          -  Recent punction of noncompressive artery

          -  Stroke in the last 6 months

          -  Major intervention o major traumatism in the last 6 weeks

          -  Hypersensibility to urokinase or alteplase

          -  Severe Liver or kidney failure

          -  Inclusion in another interventional study in the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>5</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>LLeida</city>
        <state>Catalunya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>July 15, 2011</last_update_submitted>
  <last_update_submitted_qc>July 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hospital Universitari Vall d'Hebron Research Institute</name_title>
    <organization>Hospital Universitari Vall d'Hebron Research Institute</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Empyema</mesh_term>
    <mesh_term>Pleural Diseases</mesh_term>
    <mesh_term>Empyema, Pleural</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

